Anti-fungal therapy at the HAART of viral therapy (Q43931072)

28 November 2017

title

Anti-fungal therapy at the HAART of viral therapy (English)

1 reference

28 November 2017

1

1 reference

28 November 2017

2

1 reference

28 November 2017

publication date

1 April 2002

1 reference

28 November 2017

published in

Trends in Microbiology

1 reference

28 November 2017

volume

10

1 reference

28 November 2017

issue

4

1 reference

28 November 2017

page(s)

173-177

1 reference

Relationship between fluconazole sensitivity of Candida albicans isolates from HIV positive patients and serotype, adherence and CD4+ lymphocyte count.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

The structure and function of the aspartic proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Pepstatin, a new pepsin inhibitor produced by Actinomycetes

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Evolution in the structure and function of aspartic proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Targeting the HIV-protease in AIDS therapy: a current clinical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Active human immunodeficiency virus protease is required for viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Retroviral proteinases. A second front against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Development of drug resistance to HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

A second gene for a secreted aspartate proteinase in Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Three distinct secreted aspartyl proteinases in Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Multiplicity of genes encoding secreted aspartic proteinases in Candida species.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Differential regulation of SAP8 and SAP9, which encode two new members of the secreted aspartic proteinase family in Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Elevated aspartic proteinase secretion and experimental pathogenicity of Candida albicans isolates from oral cavities of subjects infected with human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

High aspartyl proteinase production and vaginitis in human immunodeficiency virus-infected women

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Differential activation of a Candida albicans virulence gene family during infection

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

In vivo analysis of secreted aspartyl proteinase expression in human oral candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

In vivo expression and localization of Candida albicans secreted aspartyl proteinases during oral candidiasis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Secreted aspartic proteinase (Sap) activity contributes to tissue damage in a model of human oral candidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Modulation of experimental systemic murine candidosis by intravenous pepstatin

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Role of aspartic proteases in disseminated Candida albicans infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

HIV-Protease Inhibitors Reduce Cell Adherence of Candida Albicans Strains by Inhibition of Yeast Secreted Aspartic Proteases

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

Virulence factors of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0966-842X%2802%2902330-2

7 January 2021

10.1016/S0966-842X(02)02330-2

Identifiers

DOI

1 reference

28 November 2017

1 reference